Kineta (United States)

Recent papers from Kineta (United States)

1. Use of split intein and myotropic AAV vectors enables effective preclinical gene therapy for dysferlinopathyScience Translational Medicine · 2026
2. Decline of neurogenic thoracic outlet surgery in Washington State workers’ compensation: Effective use of a medical treatment guidelineJournal of Occupational and Environmental Medicine · 2026
3. Abstract CT068: Interim results of the ongoing phase 1-2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumorsCancer Research · 2024
4. Abstract P21: VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid LeukemiaBlood Cancer Discovery · 2024
5. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumorsFrontiers in Immunology · 2023
6. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsFrontiers in Oncology · 2023
7. Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitisLara D. Veeken · 2023
8. Lassa antiviral LHF-535 protects guinea pigs from lethal challengeScientific Reports · 2022
9. A potent Lassa virus antiviral targets an arenavirus virulence determinantPLoS Pathogens · 2018
10. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trialPLoS ONE · 2017
11. Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic painProceedings of the National Academy of Sciences · 2017
12. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwayJournal of Virology · 2015
13. Dalazatide, A First-In-Class Blocker Of The Kv1.3 Potassium Channel On Effector Memory T Cells: Safety, Tolerability And Proof Of Concept Immunomodulation In Patients With Active Plaque PsoriasisBasel Life Science Week · 2015
14. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar developmentmAbs · 2015
15. Headache After Traumatic Brain Injury: A National Survey of Clinical Practices and Treatment ApproachesPM&R · 2014
16. Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseasesThe FASEB Journal · 2014
17. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistanceProceedings of the National Academy of Sciences · 2013
18. Isoflavone Agonists of IRF-3 Dependent Signaling Have Antiviral Activity against RNA VirusesJournal of Virology · 2012
19. Development of a competition ELISA to assess stability and measure ShK‐186 in plasma samplesThe FASEB Journal · 2011
20. Genotypic Characterization of an Epithelial Cell Line for the Study of Parasite–Epithelial InteractionsJournal of Parasitology · 2008